This site is intended for health professionals only
Sunday 16 June 2019
Share |

Topic: drug development

March 22, 2019
Cardiff University launches Medicines Discovery Institute
Cardiff University is stepping up the development of new drugs for mental health and central nervous system conditions, with the launch of the Medicines Discovery Institute.
 
Focusing on areas of unmet clinical need, the new institute will develop novel medications to improve the lives of people across the world.
 
October 17, 2018
ImraldiTM approved in the European Union for 13 of the same complex autoimmune conditions as its reference product is now available through the NHS

ImraldiTM is approved in the European Union (EU) for 13 of the same complex autoimmune conditions as its reference product and is now available in the UK via the NHS.
 
Imraldi is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis; enthesitis-related arthritis), axial spondyloarthritis (ankylosing spondylitis (AS) and axial spondyloarthritis with radiographic evidence of AS).
 

August 30, 2018
The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.

The European Commission has approved Vyxeos 44 mg/100mg powder for concentrate for solution for infusion for the treatment of adults with newly-diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes, manufacturer Jazz Pharmaceuticals has announced.
 
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ration of daunorubicin and cytarabine, Jazz Pharmaceuticals said.
 
The EC approval extends to all European member states as well as Iceland, Norway sand Liechtenstein.

July 12, 2018
Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.

Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.
 
The drug is already licensed in the UK for treating rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS). It will now be available to patients with adult onset stills disease (AOSD) and systemic-onset juvenile idiopathic arthritis (SIJA), which impacts children under the age of 16 years.
 

July 4, 2018
A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.

A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.
 
This month [June 2 2018], the organisation announced the launch of a Phase I Clinical Trial of its lead product, Hair Stimulating Complex, to treat the condition.
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

April 19, 2018
<p>Consortium encourages patients to get involved in the drug development and approval processes</p>

A new collaboration involving 34 public and private partners has been formed in an effort  to enable patients to be engaged in drug development and approval processes.

 

April 19, 2018
<p>Consortium encourages patients to get involved in the drug development and approval processes</p>

A new collaboration involving 34 public and private partners has been formed in an effort  to enable patients to be engaged in drug development and approval processes.

 

April 6, 2018
Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells

Boehringer Ingelheim and OSE Immunotherapeutics have announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.

 

January 23, 2018
The trial met its primary endpoint of percentage of patients on erenumab (AMG 334) achieving at least a 50% reduction of migraine days versus placebo, and all secondary endpoints

Novartis has announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

 

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

August 19, 2015
Antibiotic Research UK will announce at its Annual General meeting its first research programme to tackle antibiotic resistant bacteria (superbugs)
August 19, 2015
Antibiotic Research UK will announce at its Annual General meeting its first research programme to tackle antibiotic resistant bacteria (superbugs)
August 10, 2015
Cancer Research UK’s Drug Discovery Committee* has awarded Newcastle University’s Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials

The award will be given over five years and is designed to help build on Newcastle’s success in drug development. The extra money will help fund a programme of six to eight research projects, which will examine new strategies to develop medicines for cancer treatment.

August 10, 2015
Cancer Research UK’s Drug Discovery Committee* has awarded Newcastle University’s Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials

The award will be given over five years and is designed to help build on Newcastle’s success in drug development. The extra money will help fund a programme of six to eight research projects, which will examine new strategies to develop medicines for cancer treatment.

July 9, 2015
Zevtera® (Ceftobiprole medocaril): the latest generation Cephalosporin with broad-spectrum of activity launches in the UK
May 21, 2015
Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase III study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase III study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

May 14, 2015
Jim O’Neills Review on Antimicrobial Resistance launches their third interim report. Amongst the report’s recommendations is the creation of a $2 billion global fund to be spent over five years to assist organisations pay for their R&D on developing new antibiotics. Grants will be awarded from this fund, which will delink the reward side of antibiotic drug development from sales and should incentivise organisations to get back into the antibiotic development space. Global fund monies will be used to finance blue skies research into new antibiotics and diagnostics and encourage innovative partnerships at early development stages between academia and industry.
April 29, 2015
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
 
Ursula Theuretzbacher, the founder of the Centre for Anti-Infective Agents in Vienna, led the session, which gave a review of the research and development programmes from across some of the most innovative and nimble European biotech companies.

April 28, 2015
Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p=0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed.

Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p=0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed.

April 27, 2015
The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana®. The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or venous thromboembolism, involving 21,105 and 8,292 patients, respectively. Daiichi Sankyo looks forward to receiving approval decision by the European Commission soon, which is the basis for marketing authorisation in all European Union member states.
  • The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana®.
  •  The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or venous thromboembolism, involving 21,105 and 8,292 patients, respectively. 
March 19, 2015
Ablynx announced that it has administered the first dose in the Phase IIb study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in combination with methotrexate (MTX) in adult patients with active RA, despite MTX therapy. The study aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.

Ablynx announced that it has administered the first dose in the Phase IIb study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in combination with methotrexate (MTX) in adult patients with active RA, despite MTX therapy. The study aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.
 

March 10, 2015
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine